Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer

Founded Year

2012

Stage

Series B | Alive

Total Raised

$1.23M

Last Raised

$1.23M | 3 yrs ago

About Sano V

Sano V is focused on research and development of a men's health platform for the treatment of erectile dysfunction.

Sano V Headquarter Location

Singapore

Latest Sano V News

QT Vascular, partners invest $1.23m in R&D firm through share subscription, Companies & Markets News & Top Stories - The Straits Times

Dec 21, 2018

The Straits Times Published They can read the article in full after signing up for a free account. Share link: All done! This article is now fully available for you Read now Get unlimited access to The Straits Times and more at S$ 0.99/month. Get unlimited access at $0.99/month* Latest headlines and exclusive stories In-depth analyses and award-winning multimedia content Get access to all with our no-contract promotional package at only $0.99/month for the first 3 months* *Terms and conditions apply. SINGAPORE - Medtech company QT Vascular on Wednesday evening (Dec 19) said it has, together with other third party investors, agreed to invest in a stake in research and development firm Sano V through a share subscription for $1.23 million. The subscription will comprise some 293,018 new voting convertible preferred shares designated as "Series B preferred shares" at an issue price of $4.21 per share. QT Vascular's proportion is 83,135 Series B preferred shares amounting to about $350,000. Immediately upon completion of the subscription, QT Vascular will have an effective voting interest of 4.1 per cent in the investee company. QT Vascular is also granted a call option, where it is entitled, at any time within 90 days following a notification by Sano V of its completion of a successful six-month follow-up of its first five patients, to require all shareholders of Sano V to sell all of their shares to QT Vascular. The purchase price for the call option shares will be satisfied in cash or shares, and will be equivalent to 2.5 times of the most recent valuation of Sano V. Sano V is a company incorporated in Singapore in December 2012 which does research and development of a novel men's health platform for the treatment of erectile dysfunction.Sano V has a paid-up share capital of about $1.84 milion, comprising 320,000 ordinary sharesand 1.4 million Series A preferred shares, which are convertible into ordinary shares and carry voting rights equivalent to the number of ordinary shares into which they may be converted. For the financial year ended Dec 31, 2017 and unaudited management accounts for the nine months ended Sept 30, Sano V made a net loss after tax of $535,652 and $376,905, respectively. As at end-December 2017 and end-September 2018, Sano V had a net tangible asset value of $160,402 and net tangible liability value of $21,562, respectively. The consideration is payable in cash, and Sano V plans to use the $1.23 million raised in proceeds for its first-in-man study and general working capital. QT Vascular said it is participating in the subscription as the ongoing research and development activities being carried out by Sano V is synergistic with its own business and focus on medical solutions. "The subscription is in line with the company's plans and strategies to create new product pipelines to be developed and sold, thus enabling the company to have more business opportunities," it said. QT Vascular said it will obtain the necessary approvals, including from shareholders, if it decides to exercise the call option. QT Vascular CEO Eitan Konstantino and non-independent non-executive director Mark Wan are financial investors in Sano V, with an effective voting interest of 9.12 per cent and and 12.37 per cent respectively. Topics:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sano V

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sano V is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Sano V Patents

Sano V has filed 5 patents.

The 3 most popular patent topics include:

  • Angiology
  • Penis
  • Dosage forms
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/7/2019

6/15/2021

Mammal male reproductive system, Penis, Implants (medicine), Syndromes, Angiology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/7/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/15/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Mammal male reproductive system, Penis, Implants (medicine), Syndromes, Angiology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.